CA
NZ
UK
AU
IND
US
TotalDebtand net debt were each USD 2.4 billion at September 30, 2026. The company declared a Q3 baseCash Dividendof USD 0.50 per Class A common share, the first under its new return ofCapitalframework, and repurchased about 2.1 million Class A shares for about USD …
Retirement pre-tax adjusted operating earnings were USD 266 million versus USD 261 million. Trailing twelve month net revenues rose 6%, though the adjustedOperating Marginwas 37.8% versus 39.8% on lower alternative investment income. Total clientAssetswere USD 878 billion, up 12% from USD 785 billion, and …
Gross profit rose to USD 10.2 million from USD 6.1 million, but gross margin fell to 11.5% from 15.4% on investments inManufacturingcapacity and strategic programs. Sequentially, gross margin improved by 310 basis points onOperating Leveragefrom higher revenue. The net loss attributable to the company …
TRIKAFTA and KAFTRIO revenue was USD 2,436.9 million versus USD 2,653.6 million, so growth came from newer products. CASGEVY revenue was USD 99 million, up 30% from the second quarter and nearly six times the USD 17 million of a year earlier.
LeaseOperating Expenserose to USD 19.2 million from USD 18.5 million, production taxes rose to USD 7.5 million from USD 6.2 million, and general and administrative expense fell to USD 4.9 million from USD 5.7 million. Depletion, depreciation, amortization and accretion fell to USD 32.8 …
Selling, general and administrative expenses rose 13.2% to USD 44.0 million from USD 38.8 million on higher operating costs associated with growth.Operating Incomerose 6.8% to USD 59.5 million, or 4.7% of revenue versus 4.8%. Cumulative catch-up adjustments reduced operating income by USD 1.1 million, …
Cost of revenue, excludingDepreciationand amortization, rose to USD 99.2 million from USD 85.1 million, sales andMarketingto USD 52.0 million from USD 45.2 million, general and administrative to USD 51.4 million from USD 32.4 million, andResearch and Developmentto USD 20.3 million from USD 12.4 million. …
Product costs rose to USD 618 million from USD 471 million, operating and maintenance expenses rose to USD 639 million from USD 583 million, depreciation, depletion and amortization rose to USD 620 million from USD 564 million, and general and administrative expenses rose to …
Immunology revenue rose 16.3% to USD 9.165 billion. Skyrizi grew 22.7% to USD 5.776 billion and Rinvoq grew 23.9% to USD 2.706 billion, while Humira fell 31.2% to USD 683 million. Neuroscience revenue rose 19.4% to USD 3.389 billion, with Vraylar at USD 1.068 …
Management said a sharp rise in interest rates accelerated delinquencies, slowed resolutions and reduced agency origination volumes, which affected gain on sale.
Please wait processing your request...